Lawmakers Urged to Update FDA Authorities to Keep Up With AI

Lawmakers are being urged to modernize the Food and Drug Administration’s authority to assess and approve artificial intelligence tools and health-care products.

“I have a lot of empathy and sympathy for the FDA at the moment where they’re being asked to evaluate a new technology that they’re not really designed to evaluate right now,” said Andrew Ibrahim, chief clinical officer at health care technology company Viz.ai.

The discussion arose during a House Energy and Commerce Health Subcommittee hearing Wednesday focused on the potential of artificial intelligence in health care. In response to questions from full committee leaders Brett Guthrie (R-Ky.) ...